Global Intellectual Property Portfolio Now Includes 82 Issued Patents
ANN ARBOR, Mich.–(BUSINESS WIRE)– ENDRA Life Sciences (NASDAQ:) Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ®), announces that the European Patent Office has issued to ENDRA a new patent EP4247282 (the ˜282 patent) titled Method and System for Monitoring Tissue Temperature.
The ˜282 patent relates to a novel method and system for monitoring tissue ablation during minimally invasive thermal surgical interventions by utilizing ENDRA’s TAEUS ® system. It is related to ENDRA’s U.S. patent US11,051,883 enabling integration with existing ablation systems. ENDRA expects its method and system to be applicable to minimally invasive microwave and radiofrequency thermal ablation procedures, which continue to grow globally as a less painful alternative with shorter recovery times compared with open surgical procedures.
This issued patent, our 17th in Europe, supports ENDRA’s strategy to develop optimized hybrid ultrasound and thermoacoustic imaging systems and to broaden the potential applications for our TAEUS ® platform technology in areas with unmet clinical needs,” stated ENDRA’s Chief Executive Officer Alexander Tokman. “We continue to enhance our intellectual property portfolio to protect our technology in priority global markets, including the United States, Europe and China. Our extensive IP portfolio currently includes 82 patents issued worldwide.
About ENDRA Life Sciences Inc.ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ®), a ground-breaking technology that characterizes tissue similar to an MRI, but at 1/40th the cost and at the point of patient care. TAEUS ® is initially focused on the non-invasive assessment of fatty tissue in the liver. Steatotic liver disease (SLD, formerly known as NAFLD-NASH) is a chronic liver disease spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS ®, including non-invasive visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
Forward-Looking StatementsAll statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as approximate, “anticipate,” attempt, “believe,” “could,” “estimate,” “expect,” forecast, future, “goal,” hope, “intend,” “may,” “plan,” possible, potential, project, “seek,” “should,” “will,” would, or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: expectations with respect to FDA requirements regarding its clinical trials and de novo submission for its TAEUS liver device; estimates of the timing of future events and anticipated results of its development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches and sales; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA’s business strategy; and statements regarding ENDRA’s ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain FDA and other regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; ENDRA’s ability to maintain compliance with Nasdaq listing standards; ENDRA’s dependence on its senior management team; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106218099/en/
Company Contact:Richard JacrouxChief Financial [email protected]
Investor Relations:Yvonne BriggsAlliance Advisors IR(310) [email protected]
Source: ENDRA Life Sciences Inc.
